NRH Attenuates Age-Related Hearing Loss By Suppressing Cochlear Ferroptosis And Cellular Senescence Via Sirt3 Activation
Age-related hearing loss is a widespread issue that significantly impacts quality of life, yet effective drug treatments are currently unavailable. Scientists have been exploring the underlying causes, and emerging evidence points to the decline of a crucial molecule called NAD+ within cells, as well as specific cellular processes like “ferroptosis” and “cellular senescence” in the inner ear, as key contributors to this type of hearing loss. Ferroptosis is a unique form of cell death characterized by iron-dependent lipid peroxidation, essentially a type of cellular rusting. Cellular senescence refers to cells that have stopped dividing and accumulate with age, contributing to tissue dysfunction.
A promising new study has identified a compound, NRH, that shows potential in combating age-related hearing loss. Researchers found that administering NRH to mice improved their hearing abilities. This compound works by boosting NAD+ levels in the inner ear and activating a protective protein called Sirt3. Sirt3 plays a vital role in cellular health, and its activation by NRH helps to reduce oxidative stress—a harmful imbalance caused by reactive molecules—and prevent ferroptosis. By doing so, NRH effectively mitigates cellular senescence in the cochlea, the spiral-shaped cavity of the inner ear responsible for hearing.
In the study, NRH treatment not only improved auditory thresholds but also preserved essential structures in the inner ear, including hair cells, synapses (connections between nerve cells), and auditory neurons. Furthermore, the compound demonstrated a favorable safety profile. These findings suggest that NRH could be a significant step forward in developing pharmacological treatments for age-related hearing loss, offering hope for millions affected by this condition.
Source: link to paper